GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Inventories, Finished Goods

NurExone Biologic (TSXV:NRX) Inventories, Finished Goods : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Inventories, Finished Goods?

NurExone Biologic Inventories, Finished Goods Historical Data

The historical data trend for NurExone Biologic's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Inventories, Finished Goods Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
- - - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NurExone Biologic Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

NurExone Biologic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Inventories, Finished Goods
Comparable Companies
TSXV:SHRX TSX:MBX XCNQ:DTC TSX:SVA TSXV:MIR TSX:HBP XCNQ:ONCO TSXV:COV TSX:ONC TSXV:TTI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
NRXBF:USA J90:Germany
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
Website
https://www.nurexone.com
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines